Form 4: Travere Therapeutics Director Roy D. Baynes Executes Stock Option and Sells Shares

Director Roy D. Baynes exercised stock options and sold 10,000 shares of Travere Therapeutics (TVTX) common stock at $22 per share on February 6, 2025.

Summary

• On February 6, 2025, Roy D. Baynes, a director of Travere Therapeutics, exercised stock options to acquire 10,000 shares of common stock at a price of $17.44 per share.
• Simultaneously, Baynes sold 10,000 shares of Travere Therapeutics common stock at $22 per share.
• These transactions were executed under a pre-arranged trading plan (Rule 10b5-1) adopted on August 16, 2024.
• Following these transactions, Baynes directly owns 31,000 shares of Travere Therapeutics common stock.
• The stock option exercised was granted on May 17, 2017, and is fully vested and exercisable, with an expiration date of May 17, 2027.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports insider trading activity, which is a common occurrence. There's no indication of positive or negative implications for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company directors. It's common for executives to utilize 10b5-1 plans to manage their stock sales and avoid accusations of trading on inside information.

Comparison to Industry Standards

• Insider trading activity is closely monitored across the pharmaceutical industry.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also have executives who regularly file Form 4s related to stock option exercises and sales.
• The use of 10b5-1 plans is a standard practice among executives to ensure compliance with securities laws.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider trading activity.
• The sale of shares by a director could be perceived neutrally or slightly negatively by some investors, depending on their interpretation of the director's motives.

Key Dates

Keywords

Travere Therapeutics, TVTX, Roy D. Baynes, stock options, Form 4, insider trading, Rule 10b5-1, share sale, director